Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

0Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.
Get full text

Abstract

While the current approach to precursor hematologic conditions is to “watch and wait,” this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit–risk assessment.

Cite

CITATION STYLE

APA

Ghobrial, I. M., Gormley, N., Kumar, S. K., Mateos, M. V., Bergsagel, P. L., Chesi, M., … San Miguel, J. F. (2024). Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma. Blood Cancer Discovery, 5(3), 146–152. https://doi.org/10.1158/2643-3230.BCD-24-0022

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free